Why is there a dose left in my Mounjaro pen after four weeks?

Why manufacturers build overfill into injectable medicines

Pharmaceutical regulators require injectable medicines to contain more than the stated dose volume, because some liquid inevitably stays in the needle, the cartridge walls, and the mechanism of any pre-filled device. Without overfill, the last dose out of a pen could be short-measured. Eli Lilly's solution for Mounjaro is to load each KwikPen with enough tirzepatide solution to reliably deliver four full 0.5 ml injections, with the remainder left behind. This is standard practice across injectable biologics and is audited as part of the MHRA licensing process, it is not a quirk unique to Mounjaro.

The NHS medicines page for tirzepatide describes the pen as providing four doses per device. That framing is deliberate: the product is the four doses, not the total volume of fluid in the cartridge. Seeing liquid remain after your fourth injection means the system worked exactly as intended.

One practical note: the pen's internal counter and locking mechanism are calibrated to the four-dose limit. After the fourth injection the device locks and cannot fire again. That lock is a safety feature, not a fault. If you have questions about what to do with any Mounjaro leftover dose, that is worth discussing with your prescriber rather than a reason to attempt to reuse the pen.

Is the leftover liquid safe to use as a fifth dose?

This is a question our prescribers hear regularly, and the answer from the licensed guidance is clear: no. The residual fluid is not a validated, accurately measured dose. Because the pen is designed and tested to deliver four fixed doses, the volume remaining after the fourth injection has never been characterised as a therapeutic quantity. It could be less than a full dose, more, or contain air that entered the mechanism. Using it would mean self-administering an unverified amount of tirzepatide outside the instructions in the Patient Information Leaflet, which carries real clinical risk, particularly around tolerability and the structured titration schedule your prescriber has set.

If you feel you are not getting the full effect from your current dose, the right conversation is with your prescriber about whether a dose review is appropriate. You can find broader context on the available Mounjaro doses if you want to understand the licensed schedule before that conversation. Dose changes are clinical decisions, not DIY adjustments.

There is also a practical point worth making: the overfill amount varies between pens within the manufacturing tolerance. What looks like a consistent volume of leftover liquid is not a reliable guide to what is actually there.

How this fits into the four-dose-per-pen structure

Understanding the pen's design also resolves a related question that comes up often. Some people searching online find references to whether Mounjaro pens contain five doses, the short answer is no; the licensed device holds four, with overfill. The perception of a fifth dose is simply the overfill becoming visible once the pen locks.

SURMOUNT-1, the pivotal phase 3 trial published in the New England Journal of Medicine, was conducted with participants receiving tirzepatide exactly as specified in the licensed instructions. The weight-loss results that informed NICE's recommendation of tirzepatide in Technology Appraisal TA1026 are tied to that precise dosing regimen. Deviating from it (including by attempting to use overfill) falls outside the evidence base.

For anyone reviewing the cost side of treatment, there is one contextual link worth knowing about: our Mounjaro cost in the UK page sets out what a legitimate prescription service includes and why per-pen pricing deserves careful scrutiny. The pen you receive through a regulated pharmacy is the complete product; the overfill is not a bonus to stretch your supply.

What to do when your pen is finished

Once the fourth dose is done, recap the pen if a cap is available, then place it in a sharps bin, not in household recycling or general waste. Mounjaro pens contain a needle, and standard bin collections are not designed for sharps. Your pharmacist can advise on local sharps collection. If you ordered through nume, your pen arrives via DPD in plain, unbranded packaging; the same service includes clinical aftercare if you have questions between doses, seven days a week.

If you notice your pen did not complete an injection (the plunger stuck, the window did not clear, or you are unsure a full dose was delivered) do not attempt a second injection from the same pen. Contact your prescriber on the same day if possible. Our support team can help direct you to the right clinical advice quickly. You can also read more about how the remaining dose in a Mounjaro pen is handled in different scenarios, or explore the wider Mounjaro treatment overview for context on how the medicine works.